IO Biotech Inc
IOBT0.843USD
-0.047-5.25%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
55.54MCap. mercado
PérdidaP/E TTM
Más Datos de IO Biotech Inc Compañía
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Información de IO Biotech Inc
Símbolo de cotizaciónIOBT
Nombre de la empresaIO Biotech Inc
Fecha de salida a bolsaNov 05, 2021
Director ejecutivoDr. Mai-Britt Zocca, Ph.D.
Número de empleados80
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 05
DirecciónOle Maaloes Veh 3
CiudadCOPENHAGEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísDenmark
Código postal2200
Teléfono4570702980
Sitio Webhttps://www.iobiotech.com/
Símbolo de cotizaciónIOBT
Fecha de salida a bolsaNov 05, 2021
Director ejecutivoDr. Mai-Britt Zocca, Ph.D.
Ejecutivos de IO Biotech Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Dr. Faical Miyara, Ph.D.
Dr. Faical Miyara, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 23 de ago
Actualizado: sáb., 23 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
3.81%
Otro
49.30%
Accionistas
Accionistas
Proporción
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
3.81%
Otro
49.30%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
46.07%
Investment Advisor
7.71%
Hedge Fund
4.10%
Investment Advisor/Hedge Fund
3.46%
Research Firm
2.49%
Individual Investor
0.34%
Otro
35.83%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
2023Q2
46
22.57M
78.34%
-5.75M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lundbeckfond Ventures
13.95M
21.18%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
10.35%
--
--
Apr 11, 2025
Vivo Capital, LLC
6.17M
9.37%
--
--
Jun 30, 2025
HBM Partners AG
3.94M
5.99%
--
--
Apr 11, 2025
Novo Holdings A/S
2.51M
3.81%
-842.00K
-25.10%
Aug 11, 2025
Marshall Wace LLP
2.11M
3.2%
--
--
Jun 30, 2025
PFM Health Sciences, LP
1.97M
2.99%
-369.03K
-15.76%
Jun 30, 2025
BofA Global Research (US)
1.62M
2.45%
-36.44K
-2.21%
Jun 30, 2025
Pivotal Bioventure Partners Investment Advisor LLC
864.20K
1.31%
--
--
Jun 30, 2025
Morgan Stanley Smith Barney LLC
653.68K
0.99%
-135.78K
-17.20%
Jun 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
